582 related articles for article (PubMed ID: 22044430)
1. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
[TBL] [Abstract][Full Text] [Related]
4. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
6. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
9. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
Ter Avest PC; Fischer K; Gouw SC; Van Dijk K; Mauser-Bunschoten EP
Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
[TBL] [Abstract][Full Text] [Related]
10. Novel therapies for immune tolerance in haemophilia A.
Collins PW
Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
[TBL] [Abstract][Full Text] [Related]
11. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
12. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
Ettingshausen CE; Kreuz W
Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
[TBL] [Abstract][Full Text] [Related]
13. Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation.
Navarrete AM; Dasgupta S; Teyssandier M; Repesse Y; Delignat S; André S; Bayry J; Kaveri SV; Lacroix-Desmazes S
Thromb Haemost; 2010 Dec; 104(6):1093-8. PubMed ID: 20886186
[TBL] [Abstract][Full Text] [Related]
14. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
15. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients.
Hu G; Guo D; Key NS; Conti-Fine BM
Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A.
Madoiwa S; Yamauchi T; Hakamata Y; Kobayashi E; Arai M; Sugo T; Mimuro J; Sakata Y
J Thromb Haemost; 2004 May; 2(5):754-62. PubMed ID: 15099282
[TBL] [Abstract][Full Text] [Related]
17. Immunological aspects of inhibitor development.
Reding MT
Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
19. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
[TBL] [Abstract][Full Text] [Related]
20. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
